Abstract: A 5-(4,5-bis(4-bromophenyl)-2-(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present invention relates to a process for producing polyaspartic ester compositions by reacting cyclic ethers bearing primary amino and/or primary aminoalkyl groups with fumaric and/or maleic esters, to the polyaspartic ester compositions thus obtainable, and to the use thereof in two-component coating compositions.

Abstract: An organic light emitting display device is provided. The organic light emitting display device may include at least one light emitting part between an anode and a cathode, and the at least one light emitting part having at least one organic layer and a light emitting layer, wherein the at least one organic layer comprises a compound represented by Chemical Formula 1 or 2.

Abstract: An organic light emitting display device is provided. The organic light emitting display device may include at least one light emitting part between an anode and a cathode, and the at least one light emitting part having at least one organic layer and a light emitting layer, wherein the at least one organic layer comprises a compound represented by Chemical Formula 1 or 2.

Abstract: A metadielectric composite oligomeric organic material according to the formula: wherein C is a linear chain oligomeric polarizable core with a system of conjugated multiple and single bonds wherein the linear chain oligomeric polarizable core possesses at least two different monomers with differing electron affinity, and the different monomers are positioned within the linear chain oligomeric polarizable core such that an electron affinity gradient is present, and the differing monomers have a low HOMO-LUMO bandgap between them, and there is at least one electron-donor group, D, attached to the linear chain oligomeric polarizable core, there is at least one electron-acceptor group, A, is attached to the linear chain oligomeric polarizable core, p? and q? represent the number of electron-donor and electron-acceptor groups present, respectively, and are any integer greater than zero, and at least one resistive insulating group is covalently attached to the molecular structure at any location.

Abstract: The present invention generally relates to electrochromic compounds and the uses thereof, particularly to series of fluoroalkyl 3,4-dioxythiophene compounds and their electrochromic polymers or co-polymers. Both compositions and process for manufacturing thereof are in the scope of this invention.

Abstract: The present disclosure relates to novel thiophene monoamine based organic-inorganic hybrid perovskites, and the method of making and using the novel organic-inorganic hybrid perovskites.

Abstract: A metadielectric composite oligomeric organic material according to Formula shown in FIG. 4 wherein C is a linear chain oligomeric polarizable core with a system of conjugated multiple and single bonds wherein the linear chain oligomeric polarizable core possesses at least two different monomers with differing electron affinity, and the different monomers are positioned within the linear chain oligomeric polarizable core such that an electron affinity gradient is present, and the differing monomers have a low HOMO-LUMO bandgap between them, and there is at least one electron-donor group, D, attached to the linear chain oligomeric polarizable core, there is at least one electron-acceptor group, A, is attached to the linear chain oligomeric polarizable core, p? and q? represent the number of electron-donor and electron-acceptor groups present, respectively, and are any integer greater than zero, and at least one resistive insulating group is covalently attached to the molecular structure at any location.

Abstract: The invention provides a novel ?-halogen-substituted thiophene compound salt that has a potent LPA receptor antagonistic action and is useful as a medicament. The salt is represented by the general formula (I): (wherein R is a hydrogen atom or a methoxy group; X is a halogen atom; A is selected from the group consisting of: M is an alkali metal or an alkaline earth metal; and n is 1 when M is an alkali metal and is 2 when M is an alkaline earth metal).

Abstract: The invention relates to specific carboxamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments.

Abstract: Selective neuronal nitric oxide synthase (nNOS) inhibitor compounds designed with one or more thiophene-2-carboximidamide substituents for improved bioavailability.

Abstract: Disclosed is a fullerene derivative represented by the following formula (1): wherein FLN is a fullerene backbone, R1 is a substituted or non-substituted alkyl group with a carbon number less than or equal to 24, and Ar1 is a substituted or non-substituted aryl group with a carbon number less than or equal to 24.

Abstract: A method of preparing a porous graphene oxide material. The method includes the steps of: (1) preparing graphene oxide sheets from graphite at 40 to 170° C.; (2) providing a graphene oxide suspension containing the graphene oxide sheets; (3) heating the graphene oxide suspension with a base at 25 to 300° C. for 0.1 to 48 hours to obtain base-treated graphene oxide sheets; and (4) heating a mixture of the base-treated graphene oxide sheets and an acid at 25 to 300° C. for 0.1 to 48 hours to yield the porous graphene oxide material. Also disclosed are novel porous graphene oxide materials and methods of using these materials as catalysts.

Abstract: The present invention provides a novel aromatic amine derivative having a specific structure and an organic electroluminescence device in which an organic thin film layer comprising a single layer or plural layers including at least a light emitting layer is interposed between a cathode and an anode, wherein at least one layer in the above organic thin film layer, particularly a hole injecting layer contains the aromatic amine derivative described above in the form of a single component or a mixed component. Use of the aromatic amine derivative described above materialize an organic electroluminescence device which reduces an operating voltage and makes molecules less liable to be crystallized and which enhances a yield in producing the organic EL device and has a long lifetime.

Abstract: Organic dye for a dye-sensitized solar cell (DSSC) comprising at least one electron-acceptor unit and at least one ?-conjugated unit. Said organic dye is particularly useful in a dye-sensitized photoelectric transformation element which, in its turn, can be used in a dye-sensitized solar cell (DSSC).

Abstract: A compound containing a squaric acid or a croconic acid group as an anchoring group. The compound containing a squaric acid or a croconic acid group has formula 1: where n is 1 or 2, and D is selected from an alkyl, aryl, aralkyl, heteroalkyl, heteroaryl or heteroaralkyl substituent, and each substituent is substituted or unsubstituted.

Abstract: The present invention relates to compounds having cytostatic activity against tumor cells. The compounds of the invention are of formula (I), or derivatives hereof, wherein R0, R1, R2, A, and X have defined meanings as described in claim 1.

Abstract: A method of preparing a porous graphene oxide material. The method includes the steps of: (1) preparing graphene oxide sheets from graphite at 40 to 170° C.; (2) providing a graphene oxide suspension containing the graphene oxide sheets; (3) heating the graphene oxide suspension with a base at 25 to 300° C. for 0.1 to 48 hours to obtain base-treated graphene oxide sheets; and (4) heating a mixture of the base-treated graphene oxide sheets and an acid at 25 to 300° C. for 0.1 to 48 hours to yield the porous graphene oxide material. Also disclosed are novel porous graphene oxide materials and methods of using these materials as catalysts.

Abstract: In some embodiments, the present disclosure pertains to methods of capturing a gas from an environment by associating the environment (e.g., a pressurized environment) with a porous carbon material that comprises a plurality of pores and a plurality of nucleophilic moieties. In some embodiments, the associating results in sorption of gas components (e.g., CO2 or H2S) to the porous carbon materials. In some embodiments, the methods of the present disclosure also include a step of releasing captured gas components from porous carbon materials. In some embodiments, the releasing occurs without any heating steps by decreasing environmental pressure. In some embodiments, the methods of the present disclosure also include a step of disposing released gas components and reusing porous carbon materials. Additional embodiments of the present disclosure pertain to porous carbon materials that are used for gas capture.

Abstract: Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally.

Abstract: The present disclosure relates to 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol, a method for preparing the same, and use of 5,6,7,8-tetrahydro-6-[N,N-bis[(2-thienyl)ethyl]]amino-1-naphthol as a reference compound for determining an impurity in rotigotine or a preparation thereof.

Abstract: Disclosed herein are compounds of formula (I) and methods of inhibiting IKK? and the NF-?B signaling and mTOR pathways.

Abstract: A photoelectric conversion element which is obtained by having a thin film of fine oxide semiconductor particles support a methine-based dye that is represented by formula (1), said thin film being provided on a substrate.

Abstract: An organic semiconductor represented by the following formula (1). wherein Ar and Ar? are or are not the same as each other and each of them is independently a cyclic compound having a conjugated structure; R and R? are or are not the same as each other and each of them is independently one of a straight chain alkyl group, branched alkyl group, straight chain alkoxy group, branched alkoxy group, hydrogen, and halogen; R? is one of a straight chain alkyl group, branched alkyl group, straight chain alkoxy group, branched alkoxy group, hydrogen, and halogen; x, y, and z are multiples of 0.5, and x?z, y?z; and n is a constant of 1 to 1000.

Abstract: The invention relates to novel fullerene derivatives, to methods for their preparation and educts or intermediates used therein, to mixtures and formulations containing them, to the use of the fullerene derivatives, mixtures and formulations as organic semiconductors in, or for the preparation of, organic electronic (OE) devices, especially organic photovoltaic (OPV) devices and organic photodetectors (OPD), and to OE, OPV and OPD devices comprising, or being prepared from, these fullerene derivatives, mixtures or formulations.

Abstract: The present invention relates to a novel anthracene derivative and an organic electronic device using the same. The anthracene derivative can act as a hole injecting, hole transporting, electron injecting and transporting, or light emitting material in an organic light emitting device and an organic electronic device. In particular, the anthracene derivative can act as a light emitting host. The organic electronic device according to the present invention has excellent characteristics in views of efficiency, the driving voltage, and the stability.

Abstract: The present invention relates to acrylamide compounds which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes, and to a method for producing them. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

Abstract: An object of one embodiment of the present invention is to provide a novel oxadiazole derivative as a substance having high excitation energy, in particular, a substance having high triplet excitation energy. One embodiment of the present invention is an oxadiazole derivative represented by General Formula (G1) below. In General Formula (G1), R1 represents either an alkyl group having 1 to 4 carbon atoms or a substituted or unsubstituted aryl group having 6 to 13 carbon atoms. In General Formula (G1), R21 to R27 separately represent any one of a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, and a substituted or unsubstituted aryl group having 6 to 13 carbon atoms. In General Formula (G1), ? represents a substituted or unsubstituted arylene group having 6 to 13 carbon atoms. In General Formula (G1), Z represents either a sulfur atom or an oxygen atom.

Abstract: Provided herein are compounds of formula A-L-B, and pharmaceutically acceptable salts and stereoisomers thereof, wherein A is R1 and R2 together with the carbon atoms to which they are attached form a 1,2-phenylene ring optionally substituted with one or more R11; L is —C(R6)2—C(R6)2—; B is a heteroaromatic group defined herein; and -A1-A2- , A3, R11 and R6 are defined herein. Also disclosed are methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

Abstract: The present invention relates to methods for synthesizing tiotropium bromide following the scheme: Using the above scheme, tiotropium bromide (compound 5A) is obtained under mild conditions and with high yields.

Abstract: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.

Abstract: The present invention provides an organic compound to be used in an electrochromic device. The organic compound has excellent oxidation-reduction repeating characteristics and shows high transparency in the bleached state without showing light absorption in the visible light region. The organic compound has a structure represented by Formula [1] according to Claim 1. In Formula [1], A1 and A2 represent substituents, and at least one of A1 and A2 is an alkyl group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, or an optionally substituted aryl group. R1 represents a substituent, X represents an electrochromic portion, and n is an integer of 1 to 3.

Abstract: The invention provides novel antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit antibacterial and antiparasitic action against a wide range of human pathogens. The new classes of compounds show extended action against Gram positive bacteria including MRSA drug resistant pathogens. In the Gram-positive organisms, they specifically target and functionally inhibit microbial attachment to surfaces and biofilm formation. In Gram-negative bacteria, including enteroaggregative E. coli strains, these compounds function as pilicides by inhibiting the assembly of pilin subunits into adhesive filaments. Several of these compounds show potent antimicrobial action against Gram positive bacteria, perhaps involving novel targets. Many of the benzothiophene derivatives exhibit antimicrobial activity in the low micrograms per ml range and in blocking biofilm formation in the nanomolar range; ranges considered are well within the range of utility as therapeutics.

Abstract: This invention is directed to compounds of formula I having the structure which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.

Abstract: The present disclosure provides compositions and methods for the synthesis and use of croconaine compounds. The disclosed compounds are easily prepared from croconic acid. A halothiophene is reacted with an alkanolamine, the resulting aminothiophene is modified by appending a desired functional group to the hydroxyl group, and the modified aminothiophene is reacted with croconic acid to form the final compound. Applications of such croconaine compounds include photothermal imaging, photothermal therapy, light-activated drug release, and tissue welding.

Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3, L, and the subscript m are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions, and methods of treatment using the same, for the treatment of cystic fibrosis by administering a compound of the invention.

Abstract: This document discloses molecules having the following formulas (“Formula One” &“Formula Two” and “Formula Three”) The Ar1, Het, Ar2, R1, R2, R3, R4, and R5 are further described herein.

Abstract: Disclosed is a p-type organic semiconductor material having the formula: Each Con is the same and consists of a conjugated oligomer. Each EW is the same and consists of an electron withdrawing group. The p-type organic semiconductor material can be applied in an active layer of an optoelectronic device, such as an organic solar cell, an organic light-emitting diode, or an organic thin-film transistor.

Abstract: A method of manufacturing a fluorine-containing aromatic compound represented by the following formula (2-1) or formula (2-2): R1 is a linear perfluoroalkyl group having a carbon number of 1 to 3; X2 to X5 are a halogen atom or a hydrogen atom; R2 to R5, L1 and L2 are a monovalent hydrocarbon group having a carbon number of 1 to 12, a monovalent aromatic hydrocarbon group, a monovalent hetero aromatic group, a halogen atom, or a hydrogen atom; one or more groups selected from R2 to R5 are a monovalent hydrocarbon group having a carbon number of 1 to 12, a monovalent aromatic hydrocarbon group, or a monovalent heteroaromatic group; and m is an integer of 0 or more, n is an integer of 1 or more, and m+n is an integer of 2 or more and 6 or less.

Abstract: A novel compound represented by general formula (1), a carrier system including a carrier having the novel compound fixed thereon, and a photoelectric conversion device having the carrier system. In formula (1), Z is a C1-C50 conjugated group; R1 is a C6-C20 aromatic hydrocarbon group, a C7-C20 aromatic hydrocarbon group substituted by an aliphatic hydrocarbon group, or a C1-C20 aliphatic hydrocarbon group, each substituted by carboxyl, cyano, amino, amide, or nitro, the aliphatic hydrocarbon group being optionally interrupted by —O—, etc.; R2 is hydrogen or an optionally substituted C1-C20 hydrocarbon group; R30, R31, R32, R33, R40, R41, R42, R43, and R44 are each hydrogen or optionally substituted hydrocarbon group, and adjacent two of them may be connected to form a ring; R5 is hydrogen or cyano; and R11 is represented by formula (11-1) or (11-2), wherein n, ring A, and the like are as defined in the description.

Abstract: A method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject, a therapeutically effective amount of a compound of Formula Ia, a compound of Formula IIa, one or more compounds of Formula Ia or Formula IIa complexed with a metal core, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.

Abstract: A variety of specific compounds within the scope of formula I which are useful as PI3K inhibitors and can be employed for the treatment of autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases and tumours, and pharmaceutical compositions and kits containing said specific compounds.

Abstract: Thiophene containing water-soluble oligomers were synthesized and characterized. The photophysical properties of these compounds were studied; transient absorption spectroscopy was used to probe the triplet excited state and their ability to sensitize singlet oxygen was spectroscopically monitored in deuterated methanol. The above compounds were tested for their light activated biocidal properties against S. aureus both under UV and visible radiation. Among the oligomers studied, the terthiophene derivative was found to kill the bacteria efficiently.

Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.

Abstract: The present application relates to known and novel aryl- and hetarylcarboxamides of the formula (I) and to their use as medicaments for controlling endoparasites in animals or humans, and also to parasiticidal compositions, in particular endoparasites, comprising aryl- and hetarylcyclylcarboxamides.

Abstract: The present invention provides a high-conductivity hole transport material for reducing a photoelectron recombination reaction, and a solid-state dye-sensitized solar cell. The hole transport material is formed by using a compound having the structure of chemical formula (1) or (2) according to the present invention. The solid-state dye-sensitized solar cell comprises a hole transport material layer, which is formed by coating the compound on an inorganic oxide layer by means of photoelectrochemical polymerization or by means of thermal polymerization.

Abstract: There is provided (i) a method of analysing small molecules that may have a mass of <800 Da, in particular alkaloids, said method being generally referred to as MALDI-TOF-MS (or MALDI time-of-flight mass spectrometry), which is an acronym for a method of analysis by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. Also provided is (ii) a molecule according to formula (I) and the use of the molecule as a matrix in the analysis method.

Abstract: The present invention relates to the benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses; wherein X represents monosubstituted or bissubstituted or polysubstitued C1-C14 alkoxy, monosubstituted or bisubstituted or polysubstitued C1-C14 alkyl, monosubstituted or bisubstituted or polysubstitued C2-C14 alkenyl, monosubstituted or bisubstituted or polysubstitued C6-C14 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom; Y represents hydrogen, monosubstituted or bisubstituted or polysubstitued C1-C16 alkyl, monosubstituted or bisubstituted or polysubstitued C6-C12 aryl, or monosubstituted or bisubstituted or polysubstitued 5 to 6 membered heterocyclic group, or monosubstituted or bisubstituted or polysubstitued fused ring group containing nitrogen heteroatom.

Abstract: The present invention is directed to novel thiophene inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.